Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Horizon Therapeutics plc filed a Solicitation/Recommendation Statement on Schedule 14D-9 in connection with the Transaction Agreement dated December 11,…
Amgen completes $28B Horizon buyout that was challenged by FTC. Amgen closed its $27.8 billion acquisition of Horizon Therapeutics, completing the largest…
Amgen FY2024 product sales: TEPEZZA $1,851M, KRYSTEXXA $1,185M, UPLIZNA $379M, TAVNEOS $283M (acquired Horizon portfolio total $3,698M), first full year under…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Amgen acquired Horizon Therapeutics for approximately $27.8 billion ($116.50 per share in cash), gaining a portfolio of rare inflammatory disease medicines led by Tepezza (thyroid eye disease), Krystexxa (chronic refractory gout), and Uplizna (NMOSD). The deal overcame an FTC challenge resolved via consent order in September 2023.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Horizon Therapeutics plc (this deal) | 2022 | $27.8B | 72 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2022 deals · Amgen Inc. deals · Immunology deals